Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

AI tool aims to accelerate Alzheimer's treatment through faster referrals

Vanderbilt Health researchers have received a grant from Eli Lilly and Company, a multinational pharmaceutical company headquartered in Indianapolis, to build an artificial intelligence (AI) tool within the electronic health record system (EHR) to get patients with Alzheimer's disease to treatment faster.

5 Aug 2026

Microbiome-based therapy may increase peanut allergy tolerance in adults

Some 33 million Americans have severe food allergies. Now, researchers at Boston Children's Hospital may have found a promising solution.

5 Aug 2026

Novel drug puts cancer cells under extreme metabolic stress

Cancer cells have a voracious appetite for sugar-using it to fuel their rapid growth. This is why many scientists have tried to develop drugs that block cancer cells' metabolism by cutting off their sugar supply.

5 Aug 2026

Cryo-EM study reveals dynamic structure of human norovirus

Human norovirus is the leading cause of acute gastroenteritis worldwide and is estimated to infect 600–700 million people each year.

4 Aug 2026

New gum disease treatment kills harmful bacteria while saving beneficial microbes

Researchers at Nagoya University in Japan have created an innovative treatment for periodontitis that targets and eliminates harmful bacteria while preserving beneficial oral microbes essential for health.

4 Aug 2026

Sino Biological launches precisely characterized full-length p-Tau217 protein to advance next-generation Alzheimer’s Biomarker assay development

Sino Biological Inc. is pleased to announce the launch of its Recombinant Human p-Tau217 Protein (Cat. No. T08-50SN), a full-length, tag-free Tau reagent developed to support Alzheimer’s disease biomarker assay development, antibody evaluation, and Tau biology research.

From Sino Biological Inc. 4 Aug 2026

UCLA researchers find strategy to improve prostate cancer therapies

UCLA researchers have identified a promising strategy to make a new class of targeted cancer therapies more effective against one of the deadliest forms of prostate cancer, potentially overcoming treatment resistance that has limited their success.

3 Aug 2026

Children remain more vulnerable to influenza despite protective antibody levels

Researchers analyzing 1,518 South African household participants found that higher pre-season antibody titers were associated with lower infection risk for three of four influenza viruses studied. Children remained more susceptible after accounting for measured exposure and antibody titers, while younger children shed viral RNA longer than older adults.

3 Aug 2026

QUANTUM trial tests immune-targeting approach for primary plasma cell leukemia

The Alliance for Clinical Trials in Oncology today announced the activation of The QUANTUM Trial (Alliance A062401), a clinical study designed to test a novel, immune-targeting approach for patients newly diagnosed with primary plasma cell leukemia (PCL).

30 Jul 2026

Medical breakthrough allows kidney transplant for patient with zero options

An international research team led by the Medical University of Vienna reports on a new treatment strategy that has made a kidney transplant possible for a patient with no realistic chance of receiving a suitable donor organ.

30 Jul 2026

Scientists discover why bats survive deadly viruses without getting sick

It is a mystery that has puzzled scientists for years. How can the world's only winged mammals carry viruses that cause severe disease while rarely becoming seriously ill themselves?

29 Jul 2026

FDA grants fast track designation to Insilico's AI-designed mesothelioma drug candidate

Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that ISM6331, a novel, potential best-in-class pan-TEAD inhibitor driven by Insilico's proprietary AI, has received Fast Track Designation (FTD) from the U.S.

29 Jul 2026

A closer look at Parkinson’s brains finds tau where standard tests saw little

Researchers used single-molecule and super-resolution imaging to profile protein aggregates across six brain regions from 29 post-mortem donors, detecting high-intensity phosphorylated tau aggregates in the Parkinson’s disease putamen despite negligible conventional tau staining. PD cases with dementia showed greater tau burden than those without dementia, while the assay did not detect a PD-specific population of nanoscopic alpha-synuclein aggregates.

29 Jul 2026

Too little or too much iodine may push immunity off balance

This narrative review finds that adequate iodine supports thyroid hormone signaling, leukocyte metabolism, antioxidant defenses, and antimicrobial activity in humans and domesticated mammals. Both deficiency and sustained excess may impair immunity or promote thyroid inflammation, but precise immune-specific intake thresholds remain uncertain.

27 Jul 2026

Dengue virus infects memory B cells to evade immune defenses

Researchers at the University of Vermont Robert Larner, M.D. College of Medicine and Upstate Medical University in Syracuse, NY, have discovered that dengue virus can infect and replicate inside memory B cells, immune cells traditionally understood to help protect the body from infection.

27 Jul 2026

Phase 3 clinical trial enrolls first platinum-resistant ovarian cancer patient

The GOG Foundation, Inc. is proud to announce the enrollment of the first patient in GOG-3132/BEHOLD-Ovarian01 (NCT07286266), a global Phase 3 clinical trial titled A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants with Platinum-resistant Ovarian Cancer.

27 Jul 2026

Leerink Partners report names Carterra a core enabler of the $7 B "Lab-in-the-Loop" antibody discovery market

Carterra®, a leading provider of high-throughput surface plasmon resonance (HT-SPR) platforms for antibody and small molecule discovery, today highlighted new research from Leerink Partners identifying Carterra as a key enabling technology in the fast-growing market for AI-driven biologics drug discovery.

From Carterra Inc. 27 Jul 2026